Cardiovascular outcome trials (CVOT) conducted over the past few years in patients with type 2 diabetes (T2D) have shown that GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) reduced the risk of major adverse cardiovascular events (MACE), all-cause mortality and worsening nephropathy [1, 2]. The gene discussed is GLP1R; the disease is kidney disorder.